Tobacco use remains a leading cause of preventable morbidity and mortality worldwide, and current smoking cessation treatments are limited by low long-term efficacy. An interplay between positive and negative reinforcement drives high relapse rates. Psychedelic compounds, particularly psilocybin, have shown promising clinical outcomes for smoking cessation, yet the neurobiological and...
Emerging evidence suggests that classical psychedelics may offer therapeutic potential for opioid use disorder (OUD) by alleviating key hallmarks such as altered reward processing and dependence. However, the mechanisms behind these effects remain unclear. Our data demonstrate that a single administration of the psychedelic psilocybin (PSI) reduces conditioned behavior and withdrawal induced by...
Chronic pain is a debilitating disease with current treatments lacking efficacy and safety, therefore discovery of new treatments is crucial. Initial studies suggest that psychedelics may be feasible for targeting pain, however clinical and preclinical controlled studies are necessary to further investigate that possibility. In this study we assessed the effects of two classical psychedelics...